TG Therapeutics Inc (TGTX NASDAQ) stock market data APIs
$29.8831
0.16(0.5%)
as of March 20, 2026
Try our APIs with
free plan!
TG Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Prev. Close
29.8831
Open
30.0424
High
30.7228
Low
29.3697
52 wk Range
25.28-46.48
Market Cap
4 802 M
P/E Ratio
10.8556
Shares Outstanding
160 M
Revenue
616 M
EPS
0.14
Beta
1.86
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with TG Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get TG Therapeutics Inc data using free add-ons & libraries
Get TG Therapeutics Inc Fundamental Data
TG Therapeutics Inc Fundamental data includes:
- Net Revenue: 616 M
- EBITDA: 123 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-03
- EPS/Forecast: 0.3271
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
TG Therapeutics Inc News
New
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
TG Therapeutics, Inc. Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives NEW YORK, March 19, 2026 (GLOBE NE...
Top Research Reports for Philip Morris, Lam Research & Goldman Sachs
Monday, March 16, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Philip Morr...
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment
On February 17, 2026, ACT Capital Management disclosed a new position in Viking Therapeutics(NASDAQ:VKTX), acquiring 206,100 shares worth $7.25 million. What happened According to an SEC filing date...
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop
On February 17, 2026, ACT Capital Management disclosed a new position in TG Therapeutics(NASDAQ:TGTX), acquiring 268,875 shares worth $8,015,164. What happened According to a filing with the Securit...
Get TG Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
